3 Barriers to Incorporating VBP Models that Assess Spending, Utilization, and Outcomes for Drugs

  1. Disparate funding streams.
  2. Limited data about drug costs and effectiveness available to prescribing clinicians.
  3. Complexity in incorporating drugs into new payment approaches.
Notes: From a blog post entitled, "How Value-Based Payment Can Improve Drug Spending, Utilization, and Equity," by Kristen Ukeomah, Mark Japinga, Nitzan Arad, Christina Bush, Frank McStay and Robert Saunders.